IM Cannabis Earnings Call Transcripts
Fiscal Year 2025
-
Q1 2025 saw a return to profitability, driven by a 569% revenue surge in Germany and significant cost reductions, offsetting declines in Israel. Gross margin improved 87% year-over-year, with net profit reaching EUR 0.2 million and positive adjusted EBITDA.
Fiscal Year 2024
-
Germany drove strong revenue growth in 2024, with a 183% sales increase and improved operational efficiency leading to positive Q4 Adjusted EBITDA. Inventory write-offs impacted margins, but a robust supply chain positions the company for record sales in Q1 2025.
-
Q3 2024 saw strong revenue growth in Germany, offsetting declines in Israel due to regulatory and market challenges. Operating efficiency improved, with a focus on supply chain integration and premium products, setting the stage for accelerated German growth in 2025.
-
Q2 2024 saw a 200% sequential sales increase in Germany post-legalization, driving 11.7% year-over-year revenue growth. Gross margins were impacted by Israeli inventory write-downs, but German margins remain strong at 40%. Strategic focus is on German expansion and premium Israeli products.